SDBN Blog, News https://sdbn.org Life Science Events, Jobs, Directory, News Fri, 03 Apr 2026 18:04:42 +0000 en-US hourly 1 https://wordpress.org/?v=6.9.4 https://sdbn.org/wp-content/uploads/2021/08/SDBN-Circle-Transp.png News – San Diego Biotechnology Network https://sdbn.org 32 32 https://sdbn.org/san-diego-biotech-news/2026/04/03/grandevity-launches-vitality-and-energy-for-adults-aged-50-to-100/ GRANDEVITY Launches: Vitality and Energy for Adults Aged 50 to 100 https://feeds.feedblitz.com/~/953194343/0/sdbnblognews~GRANDEVITY-Launches-Vitality-and-Energy-for-Adults-Aged-to/ Fri, 03 Apr 2026 18:04:42 +0000 https://sdbn.org/san-diego-biotech-news/2026/04/03/grandevity-launches-vitality-and-energy-for-adults-aged-50-to-100/ [...]

]]> GRANDEVITY Definition: “Great Age, Long Life, Longevity” SAN DIEGO, April 3, 2026 /PRNewswire/ — Today, GRANDEVITY officially launches as a premium plant-based wellness brand dedicated to helping adults aged 50 to 100 complement their healthy lifestyles and embrace vibrant everyday…

Click here to view original post

Click Here to Publish/Feature Your Company or Product News with Biotech Networks

]]> https://sdbn.org/san-diego-biotech-news/2026/04/03/uc-san-diego-school-of-medicine-ranked-no-4-nationally-for-nih-funding-among-public-institutions/ UC San Diego School of Medicine Ranked No. 4 Nationally for NIH Funding Among Public Institutions https://feeds.feedblitz.com/~/953190419/0/sdbnblognews~UC-San-Diego-School-of-Medicine-Ranked-No-Nationally-for-NIH-Funding-Among-Public-Institutions/ Fri, 03 Apr 2026 17:04:43 +0000 https://sdbn.org/san-diego-biotech-news/2026/04/03/uc-san-diego-school-of-medicine-ranked-no-4-nationally-for-nih-funding-among-public-institutions/ [...]

]]>

The University of California San Diego School of Medicine ranked No. 4 among public institutions and No. 14 overall nationwide for NIH funding in 2025 as reported by the Blue Ridge Institute for Medical Research (BRIMR).

Click here to view original post

Click Here to Publish/Feature Your Company or Product News with Biotech Networks

]]> https://sdbn.org/wp-content/uploads/2026/04/uc-san-diego-school-of-medicine-ranked-no-4-nationally-for-nih-funding-among-public-institutions-1024x536.png https://sdbn.org/san-diego-biotech-news/2026/04/03/agenus-announces-data-from-phase-ii-study-of-botbal-in-combination-with-agent-797-in-pd-1-refractory-gastroesophageal-cancer-to-be-presented-at-aacr-2026/ Agenus Announces Data from Phase II Study of BOT+BAL in Combination with agent-797 in PD-1 Refractory Gastroesophageal Cancer to be Presented at AACR 2026 https://feeds.feedblitz.com/~/953173229/0/sdbnblognews~Agenus-Announces-Data-from-Phase-II-Study-of-BOTBAL-in-Combination-with-agent-in-PD-Refractory-Gastroesophageal-Cancer-to-be-Presented-at-AACR/ Fri, 03 Apr 2026 12:04:44 +0000 https://sdbn.org/san-diego-biotech-news/2026/04/03/agenus-announces-data-from-phase-ii-study-of-botbal-in-combination-with-agent-797-in-pd-1-refractory-gastroesophageal-cancer-to-be-presented-at-aacr-2026/ [...]

]]> LEXINGTON, Mass.–(BUSINESS WIRE)—- $AGEN #AACR2026–Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology innovation, today announced that data from an investigator-initiated Phase II trial conducted at Memorial Sloan Kettering Cancer Center will be presented at the American Association for Cancer Research (AACR) Annual Meeting, taking place April 17–22, 2026, in San Diego, CA. The study evaluates botensilimab (BOT) and balstilimab (BAL) in combination with agenT-797, an allogeneic iNKT cell therapy developed
Click here to view original post

Click Here to Publish/Feature Your Company or Product News with Biotech Networks

]]> https://sdbn.org/san-diego-biotech-news/industry-news/2026/04/02/top-10-organoid-companies/ Top 10 Organoid Companies https://feeds.feedblitz.com/~/953121908/0/sdbnblognews~Top-Organoid-Companies/ Thu, 02 Apr 2026 21:23:08 +0000 https://sdbn.org/san-diego-biotech-news/industry-news/2026/04/02/top-10-organoid-companies/ [...]

]]> The past year marked a proverbial inflection point for organoid models designed to uncover biological insights previously unattainable through traditional cell culture experiments or animal models.

The FDA in October approved the first-ever investigational new drug (IND) submission supported solely through human vascularized organoid-based combination studies, without relying on traditional animal efficacy proof-of-concept (POC) testing. The IND application by SillaJen enabled the South Korea-based developer of oncolytic virus immunotherapeutics to begin clinical trials for a combination therapy consisting of tislelizumab or paclitaxel and BAL0891, a dual inhibitor of threonine tyrosine kinase (TTK) and polo-like kinase 1 (PLK).

SillaJen’s combo therapy incorporating BAL0891 is being evaluated in a Phase I trial (NCT05768932) whose primary completion date is estimated at December 24. SillaJen’s IND included preclinical efficacy data generated through the vascularized tumor immune microenvironment model (vTIME) developed by Qureator.

The vTIME platform and SillaJen’s trial are early examples of the shift…
Click here to view original post

Click Here to Publish/Feature Your Company or Product News with Biotech Networks

]]> https://sdbn.org/san-diego-biotech-news/2026/04/02/acurion-closes-oversubscribed-4-3-million-seed-round-to-advance-ai-driven-precision-oncology-platform/ Acurion Closes Oversubscribed $4.3 Million Seed Round to Advance AI-Driven Precision Oncology Platform https://feeds.feedblitz.com/~/953098406/0/sdbnblognews~Acurion-Closes-Oversubscribed-Million-Seed-Round-to-Advance-AIDriven-Precision-Oncology-Platform/ Thu, 02 Apr 2026 17:05:42 +0000 https://sdbn.org/san-diego-biotech-news/2026/04/02/acurion-closes-oversubscribed-4-3-million-seed-round-to-advance-ai-driven-precision-oncology-platform/ [...]

]]>

Funding led by TK Partners supports further clinical validation, regulatory preparation, and commercialization of OncoGaze™ SAN DIEGO, April 2, 2026 /PRNewswire/ — Acurion, a precision oncology technology company advancing AI-driven cancer biomarker detection through its OncoGaze™…

Click here to view original post

Click Here to Publish/Feature Your Company or Product News with Biotech Networks

]]> https://sdbn.org/wp-content/uploads/2026/04/acurion-closes-oversubscribed-4-3-million-seed-round-to-advance-ai-driven-precision-oncology-platform-1024x270.jpg https://sdbn.org/san-diego-biotech-news/2026/04/02/top-cancer-scientist-thales-papag-papagiannakopoulos-joins-salk-institute/ Top cancer scientist Thales “PapaG” Papagiannakopoulos joins Salk Institute https://feeds.feedblitz.com/~/953098409/0/sdbnblognews~Top-cancer-scientist-Thales-%e2%80%9cPapaG%e2%80%9d-Papagiannakopoulos-joins-Salk-Institute/ Thu, 02 Apr 2026 17:05:40 +0000 https://sdbn.org/san-diego-biotech-news/2026/04/02/top-cancer-scientist-thales-papag-papagiannakopoulos-joins-salk-institute/ [...]

]]> LA JOLLA—The Salk Institute has recruited globally renowned cancer scientist Thales “PapaG” Papagiannakopoulos, PhD, to join its faculty as a professor beginning in September 2026. Papagiannakopoulos has served as a faculty member at NYU Grossman School of Medicine since 2015, where he is currently a tenured associate professor in the Department of Pathology at NYU’s Grossman School of Medicine and the Perlmutter Cancer Center. He will bring to Salk additional expertise in cancer metabolism, cancer immunology, and tumor-host communications, opening new opportunities for collaboration within Salk’s National Cancer Institute (NCI) Designated Cancer Center and across the Institute.

Cancer research expert Thales “PapaG” Papagiannakopoulos, PhD, joins the Salk Institute.
Cancer research expert Thales “PapaG” Papagiannakopoulos, PhD, joins the Salk Institute.
Click here for a high-resolution image.
Credit: Sim Singh

“Thales is the kind of scientist who starts with fundamental…
Click here to view original post

Click Here to Publish/Feature Your Company or Product News with Biotech Networks

]]> https://sdbn.org/san-diego-biotech-news/2026/04/02/unprecedented-early-stage-cancer-detection-presented-at-aacr-2026/ Unprecedented Early-Stage Cancer Detection Presented at AACR 2026 https://feeds.feedblitz.com/~/953090867/0/sdbnblognews~Unprecedented-EarlyStage-Cancer-Detection-Presented-at-AACR/ Thu, 02 Apr 2026 16:05:31 +0000 https://sdbn.org/san-diego-biotech-news/2026/04/02/unprecedented-early-stage-cancer-detection-presented-at-aacr-2026/ [...]

]]> GLASGOW, Scotland–(BUSINESS WIRE)–Dxcover, a global leader in AI-enabled technologies, today announced the presentation of multiple studies at the American Association for Cancer Research (AACR) Annual Meeting taking place in San Diego, California this month. The company will present data as part of key sessions focused on Early Detection Approaches – specifically Stage I and II cancers, which can be treated when detected, but are elusive to other screening protocols. Matthew Baker, PhD, CEO
Click here to view original post

Click Here to Publish/Feature Your Company or Product News with Biotech Networks

]]> https://sdbn.org/san-diego-biotech-news/2026/04/02/tiktok-loves-these-skin-care-trends-should-you/ TikTok Loves These Skin Care Trends — Should You? https://feeds.feedblitz.com/~/953081909/0/sdbnblognews~TikTok-Loves-These-Skin-Care-Trends-%e2%80%94-Should-You/ Thu, 02 Apr 2026 15:05:24 +0000 https://sdbn.org/san-diego-biotech-news/2026/04/02/tiktok-loves-these-skin-care-trends-should-you/ [...]

]]>

Sardine fast? Slugging? Red light mask? Before you try it, see what UC San Diego dermatologist Swati Kannan, MD, says about the viral skin care advice taking over your feed.

Click here to view original post

Click Here to Publish/Feature Your Company or Product News with Biotech Networks

]]> https://sdbn.org/wp-content/uploads/2026/04/tiktok-loves-these-skin-care-trends-should-you-1024x536.jpg https://sdbn.org/san-diego-biotech-news/2026/04/02/illumina-announces-changes-to-board-of-directors/ Illumina Announces Changes to Board of Directors https://feeds.feedblitz.com/~/953069474/0/sdbnblognews~Illumina-Announces-Changes-to-Board-of-Directors/ Thu, 02 Apr 2026 14:21:45 +0000 https://sdbn.org/san-diego-biotech-news/2026/04/02/illumina-announces-changes-to-board-of-directors/ [...]

]]>

David P. King nominated to support next phase of growth and innovation; Frances Arnold, Robert S. Epstein, and Gary S. Guthart to retire from the Board SAN DIEGO, April 2, 2026 /PRNewswire/ — Illumina, Inc. (NASDAQ: ILMN) today announced changes to its Board of Directors. Frances Arnold,…

Click here to view original post

Click Here to Publish/Feature Your Company or Product News with Biotech Networks

]]> https://sdbn.org/wp-content/uploads/2026/04/illumina-announces-changes-to-board-of-directors-1024x293.jpg https://sdbn.org/san-diego-biotech-news/2026/04/02/adagene-announces-pricing-of-us70-0-million-public-offering-of-adss/ Adagene Announces Pricing of US$70.0 Million Public Offering of ADSs https://feeds.feedblitz.com/~/953059487/0/sdbnblognews~Adagene-Announces-Pricing-of-US-Million-Public-Offering-of-ADSs/ Thu, 02 Apr 2026 13:05:24 +0000 https://sdbn.org/san-diego-biotech-news/2026/04/02/adagene-announces-pricing-of-us70-0-million-public-offering-of-adss/ [...]

]]>

SAN DIEGO and SUZHOU, China, April 02, 2026 (GLOBE NEWSWIRE) — Adagene Inc. (“Adagene” or the “Company”) (Nasdaq: ADAG), a company committed to transforming the discovery and development of novel antibody-based therapies, today announced the pricing of its underwritten public offering of 18,666,000 American depositary shares, or ADSs, each representing 1.25 ordinary shares of the Company, par value US$0.0001 per share, at the offering price of US$3.75 per ADS, representing the 30-day volume-weighted average price (“VWAP”).

Click here to view original post

Click Here to Publish/Feature Your Company or Product News with Biotech Networks

]]> https://sdbn.org/san-diego-biotech-news/2026/04/02/calidi-biotherapeutics-to-present-new-data-on-its-lead-asset-cld-401-at-the-aacr-annual-meeting-in-april-2026/ Calidi Biotherapeutics to Present New Data on Its Lead Asset CLD-401 at the AACR Annual Meeting in April 2026 https://feeds.feedblitz.com/~/953059484/0/sdbnblognews~Calidi-Biotherapeutics-to-Present-New-Data-on-Its-Lead-Asset-CLD-at-the-AACR-Annual-Meeting-in-April/ Thu, 02 Apr 2026 13:05:24 +0000 https://sdbn.org/san-diego-biotech-news/2026/04/02/calidi-biotherapeutics-to-present-new-data-on-its-lead-asset-cld-401-at-the-aacr-annual-meeting-in-april-2026/ [...]

]]> SAN DIEGO, April 02, 2026 (GLOBE NEWSWIRE) — Calidi Biotherapeutics, Inc. (NYSE American: CLDI) (“Calidi” or the “Company”), a biotechnology company pioneering the development of targeted genetic medicines, will present new data at the American Association of Cancer Research (AACR) annual meeting in San Diego, California from April 17-22, 2026. The Company will showcase new data on CLD-401, a systemically delivered oncolytic virus that is designed to express high levels of IL-15 superagonist (“IL-15 SA”) only in the tumor microenvironment (“TME”), currently in IND-enabling studies.

Click here to view original post

Click Here to Publish/Feature Your Company or Product News with Biotech Networks

]]> https://sdbn.org/san-diego-biotech-news/2026/04/02/exactice-medical-and-imsonic-announce-product-development-and-supply-agreement-for-aim-device-in-transseptal-procedures/ Exactice Medical and ImSonic Announce Product Development and Supply Agreement for AIM Device in Transseptal Procedures https://feeds.feedblitz.com/~/953059481/0/sdbnblognews~Exactice-Medical-and-ImSonic-Announce-Product-Development-and-Supply-Agreement-for-AIM-Device-in-Transseptal-Procedures/ Thu, 02 Apr 2026 13:05:24 +0000 https://sdbn.org/san-diego-biotech-news/2026/04/02/exactice-medical-and-imsonic-announce-product-development-and-supply-agreement-for-aim-device-in-transseptal-procedures/ [...]

]]> SAN DIEGO–(BUSINESS WIRE)–Exactice Medical, Inc. today announced a definitive agreement with ImSonic Medical, Inc. to complete advanced prototype development of its AIM device—the industry’s first combined imaging and transseptal access solution, designed to make transseptal procedures faster, safer, and more cost-effective. Exactice’s proprietary AIM device combines 2D/3D intracardiac echocardiography (ICE) with a fully integrated, deployable steerable needle guide. The needle guide remains
Click here to view original post

Click Here to Publish/Feature Your Company or Product News with Biotech Networks

]]> https://sdbn.org/san-diego-biotech-news/2026/04/01/spatial-biology/ Spatial Biology https://feeds.feedblitz.com/~/952841333/0/sdbnblognews~Spatial-Biology/ Wed, 01 Apr 2026 18:05:28 +0000 https://sdbn.org/san-diego-biotech-news/2026/04/01/spatial-biology/ [...]

]]> Spatial biology is a rapidly advancing discipline that examines biological molecules (such as DNA, RNA, and proteins) within their native locations in tissues. This approach offers critical insight into how cancer and immune cells interact within the tumor microenvironment.

Beginning in the 20th century, techniques such as immunohistochemistry and in situ hybridization allowed researchers to localize proteins and nucleic acid sequences directly in tissue samples. However, these analyses were typically limited to a single marker at a time. More recently, advances in high-throughput sequencing and mass spectrometry enable the simultaneous analysis of hundreds, or even thousands, of molecules while preserving spatial context. To explore the future of spatial biology, we spoke with four companies pioneering these technologies.

Spatial transcriptomics

The transcriptome is the complete collection of RNA produced in a cell or tissue at a given time. It reflects active gene expression, which varies with disease state…
Click here to view original post

Click Here to Publish/Feature Your Company or Product News with Biotech Networks

]]> https://sdbn.org/san-diego-biotech-news/2026/04/01/nih-awards-15-8-million-to-university-of-california-for-study-of-latino-brain-health/ NIH Awards $15.8 Million to University of California for Study of Latino Brain Health https://feeds.feedblitz.com/~/952841330/0/sdbnblognews~NIH-Awards-Million-to-University-of-California-for-Study-of-Latino-Brain-Health/ Wed, 01 Apr 2026 18:05:28 +0000 https://sdbn.org/san-diego-biotech-news/2026/04/01/nih-awards-15-8-million-to-university-of-california-for-study-of-latino-brain-health/ [...]

]]>

A multisite study led by UC San Diego and UC Davis will examine changes in brain imaging, blood biomarkers and cognition over time in Latino and Hispanic people.

Click here to view original post

Click Here to Publish/Feature Your Company or Product News with Biotech Networks

]]> https://sdbn.org/wp-content/uploads/2026/04/nih-awards-15-8-million-to-university-of-california-for-study-of-latino-brain-health-1024x536.png https://sdbn.org/san-diego-biotech-news/2026/04/01/calidi-biotherapeutics-to-present-new-data-on-its-differentiated-approach-to-in-situ-t-cell-engagers-including-a-new-candidate-targeting-trop-2-at-the-aacr-annual-meeting-in-april-2026/ Calidi Biotherapeutics to Present New Data on Its Differentiated Approach to In Situ T-Cell Engagers Including a New Candidate Targeting TROP-2 at the AACR Annual Meeting in April 2026 https://feeds.feedblitz.com/~/952771844/0/sdbnblognews~Calidi-Biotherapeutics-to-Present-New-Data-on-Its-Differentiated-Approach-to-In-Situ-TCell-Engagers-Including-a-New-Candidate-Targeting-TROP-at-the-AACR-Annual/ Wed, 01 Apr 2026 13:07:28 +0000 https://sdbn.org/san-diego-biotech-news/2026/04/01/calidi-biotherapeutics-to-present-new-data-on-its-differentiated-approach-to-in-situ-t-cell-engagers-including-a-new-candidate-targeting-trop-2-at-the-aacr-annual-meeting-in-april-2026/ [...]

]]>

SAN DIEGO, April 01, 2026 (GLOBE NEWSWIRE) — Calidi Biotherapeutics, Inc. (NYSE American: CLDI) (“Calidi” or the “Company”), a biotechnology company pioneering the development of targeted genetic medicines, will present new data at the American Association of Cancer Research (AACR) annual meeting in San Diego, California from April 17-22, 2026. The Company will demonstrate new data on its approach of simultaneously activating T-cells while inducing the expression of T-cell engagers specifically in situ in the tumor microenvironment (TME).

Click here to view original post

Click Here to Publish/Feature Your Company or Product News with Biotech Networks

]]> https://sdbn.org/san-diego-biotech-news/2026/04/01/oncolytics-biotech-completes-domicile-change-to-the-united-states/ Oncolytics Biotech® Completes Domicile Change to the United States https://feeds.feedblitz.com/~/952771910/0/sdbnblognews~Oncolytics-Biotech%c2%ae-Completes-Domicile-Change-to-the-United-States/ Wed, 01 Apr 2026 13:07:28 +0000 https://sdbn.org/san-diego-biotech-news/2026/04/01/oncolytics-biotech-completes-domicile-change-to-the-united-states/ [...]

]]>

SAN DIEGO, April 01, 2026 (GLOBE NEWSWIRE) — Oncolytics Biotech® Inc. (Nasdaq: ONCY) (“Oncolytics” or the “Company”), a clinical-stage immunotherapy company developing pelareorep, today announced the completion of the previously announced change in the jurisdiction of incorporation of Oncolytics from the Province of Alberta in Canada to the State of Nevada in the United States (the “Domestication”) through a series of transactions in which the Company first continued its existence from the Province of Alberta in Canada to the Province of British Columbia in Canada on March 17, 2026. The Company will retain its office in Calgary, while the San Diego office will become the Company’s new headquarters.

Click here to view original post

Click Here to Publish/Feature Your Company or Product News with Biotech Networks

]]> https://sdbn.org/san-diego-biotech-news/2026/04/01/voro-therapeutics-to-present-new-preclinical-data-on-primebody-platform-and-vor-101-at-upcoming-aacr-2026-and-aet-europe-conferences/ Voro Therapeutics to Present New Preclinical Data on PrimeBody™ Platform and VOR-101 at Upcoming AACR 2026 and AET Europe Conferences https://feeds.feedblitz.com/~/952771847/0/sdbnblognews~Voro-Therapeutics-to-Present-New-Preclinical-Data-on-PrimeBody%e2%84%a2-Platform-and-VOR-at-Upcoming-AACR-and-AET-Europe-Conferences/ Wed, 01 Apr 2026 13:07:27 +0000 https://sdbn.org/san-diego-biotech-news/2026/04/01/voro-therapeutics-to-present-new-preclinical-data-on-primebody-platform-and-vor-101-at-upcoming-aacr-2026-and-aet-europe-conferences/ [...]

]]> SAN DIEGO–(BUSINESS WIRE)– #AACR2026–Voro Therapeutics, a biotechnology company pioneering tumor-activated biologics to improve the safety and efficacy of cancer therapies, today announced upcoming oral presentations at the American Association for Cancer Research (AACR) Annual Meeting 2026 and the Antibody Engineering & Therapeutics (AET) Europe conference. Voro Therapeutics will present new preclinical data showcasing the power of its proprietary PrimeBody biologics platform and the broad therapeu
Click here to view original post

Click Here to Publish/Feature Your Company or Product News with Biotech Networks

]]> https://sdbn.org/san-diego-biotech-news/2026/04/01/janux-therapeutics-announces-development-candidate-nomination-under-bristol-myers-squibb-collaboration-triggering-35-million-milestone-payment/ Janux Therapeutics Announces Development Candidate Nomination Under Bristol Myers Squibb Collaboration, Triggering $35 Million Milestone Payment https://feeds.feedblitz.com/~/952771850/0/sdbnblognews~Janux-Therapeutics-Announces-Development-Candidate-Nomination-Under-Bristol-Myers-Squibb-Collaboration-Triggering-Million-Milestone-Payment/ Wed, 01 Apr 2026 13:07:27 +0000 https://sdbn.org/san-diego-biotech-news/2026/04/01/janux-therapeutics-announces-development-candidate-nomination-under-bristol-myers-squibb-collaboration-triggering-35-million-milestone-payment/ [...]

]]> SAN DIEGO–(BUSINESS WIRE)–Janux Therapeutics, Inc. (Nasdaq: JANX) (Janux), a clinical-stage biopharmaceutical company developing a broad pipeline of novel immunotherapies, today announced the nomination of a development candidate under its collaboration and exclusive worldwide license agreement with Bristol Myers Squibb. The milestone was achieved following the identification of a tumor-activated therapeutic, utilizing Janux’s TRACTr platform, targeting an undisclosed solid tumor antigen expr
Click here to view original post

Click Here to Publish/Feature Your Company or Product News with Biotech Networks

]]> https://sdbn.org/san-diego-biotech-news/2026/04/01/vetology-expands-public-ai-validation-dashboard-to-11-metrics-per-classifier-commits-to-ongoing-model-retraining/ Vetology Expands Public AI Validation Dashboard to 11 Metrics Per Classifier, Commits to Ongoing Model Retraining https://feeds.feedblitz.com/~/952771916/0/sdbnblognews~Vetology-Expands-Public-AI-Validation-Dashboard-to-Metrics-Per-Classifier-Commits-to-Ongoing-Model-Retraining/ Wed, 01 Apr 2026 13:07:11 +0000 https://sdbn.org/san-diego-biotech-news/2026/04/01/vetology-expands-public-ai-validation-dashboard-to-11-metrics-per-classifier-commits-to-ongoing-model-retraining/ [...]

]]>

Company publishes full statistical profiles for 89+ classifiers, reinforcing that building AI is only half the job. SAN DIEGO, April 1, 2026 /PRNewswire/ — Vetology, a provider of AI-generated radiology screening reports and board-certified veterinary teleradiology, today expanded its…

Click here to view original post

Click Here to Publish/Feature Your Company or Product News with Biotech Networks

]]> https://sdbn.org/san-diego-biotech-news/2026/03/31/bioatla-reports-fourth-quarter-and-full-year-2025-financial-results-and-business-highlights/ BioAtla Reports Fourth Quarter and Full Year 2025 Financial Results and Business Highlights https://feeds.feedblitz.com/~/952567349/0/sdbnblognews~BioAtla-Reports-Fourth-Quarter-and-Full-Year-Financial-Results-and-Business-Highlights/ Tue, 31 Mar 2026 21:06:07 +0000 https://sdbn.org/san-diego-biotech-news/2026/03/31/bioatla-reports-fourth-quarter-and-full-year-2025-financial-results-and-business-highlights/ [...]

]]>

SAN DIEGO, March 31, 2026 (GLOBE NEWSWIRE) — BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics for the treatment of solid tumors, today announced its financial results for the full year and fourth quarter ended December 31, 2025 and provided business highlights.

Click here to view original post

Click Here to Publish/Feature Your Company or Product News with Biotech Networks

]]> https://sdbn.org/san-diego-biotech-news/2026/03/31/bioatla-announces-share-consolidation/ BioAtla Announces Share Consolidation https://feeds.feedblitz.com/~/952567346/0/sdbnblognews~BioAtla-Announces-Share-Consolidation/ Tue, 31 Mar 2026 21:06:07 +0000 https://sdbn.org/san-diego-biotech-news/2026/03/31/bioatla-announces-share-consolidation/ [...]

]]>

SAN DIEGO, March 31, 2026 (GLOBE NEWSWIRE) — BioAtla, Inc. (NASDAQ: BCAB or the “Company”), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics for the treatment of solid tumors, today announced that it will effect a 50-for-1 share consolidation (the “Share Consolidation”) of its common stock, par value $0.0001 per share (the “Common Stock”), that is expected to become effective on April 6, 2026 at 12:01 a.m. Eastern Time (the “Effective Date”). The Common Stock will continue to trade on The Nasdaq Capital Market under the existing symbol “BCAB” and is expected to begin trading on a split-adjusted basis when the market opens on April 6, 2026. Following the Share Consolidation, the new CUSIP number for the Common Stock will be 09077B203.

Click here to view original post

Click Here to Publish/Feature Your Company or Product News with Biotech Networks

]]> https://sdbn.org/san-diego-biotech-news/2026/03/31/new-insights-into-breast-cancer-metastasis/ New Insights into Breast Cancer Metastasis https://feeds.feedblitz.com/~/952520021/0/sdbnblognews~New-Insights-into-Breast-Cancer-Metastasis/ Tue, 31 Mar 2026 18:06:13 +0000 https://sdbn.org/san-diego-biotech-news/2026/03/31/new-insights-into-breast-cancer-metastasis/ [...]

]]>

UC San Diego researchers reveal new insights into how breast cancer spreads, shedding new light on a common cause of cancer-related deaths.

Click here to view original post

Click Here to Publish/Feature Your Company or Product News with Biotech Networks

]]> https://sdbn.org/wp-content/uploads/2026/03/new-insights-into-breast-cancer-metastasis-1024x536.png https://sdbn.org/san-diego-biotech-news/2026/03/31/katomed-a-uc-san-diego-medtech-accelerator-company-shines/ KatoMed, a UC San Diego MedTech Accelerator Company, Shines https://feeds.feedblitz.com/~/952453256/0/sdbnblognews~KatoMed-a-UC-San-Diego-MedTech-Accelerator-Company-Shines/ Tue, 31 Mar 2026 14:05:08 +0000 https://sdbn.org/san-diego-biotech-news/2026/03/31/katomed-a-uc-san-diego-medtech-accelerator-company-shines/ [...]

]]>

KatoMed, a San Diego-based startup that developed a navigation tool for spine surgery that could result in safer, less costly procedures and improved workflow for surgeons, has deep ties to UC San Diego.

Click here to view original post

Click Here to Publish/Feature Your Company or Product News with Biotech Networks

]]> https://sdbn.org/wp-content/uploads/2026/03/katomed-a-uc-san-diego-medtech-accelerator-company-shines-1024x536.jpg https://sdbn.org/san-diego-biotech-news/2026/03/31/belite-bio-announces-availability-of-annual-report-on-form-20-f-through-company-website/ Belite Bio Announces Availability of Annual Report on Form 20-F Through Company Website https://feeds.feedblitz.com/~/952439144/0/sdbnblognews~Belite-Bio-Announces-Availability-of-Annual-Report-on-Form-F-Through-Company-Website/ Tue, 31 Mar 2026 13:06:08 +0000 https://sdbn.org/san-diego-biotech-news/2026/03/31/belite-bio-announces-availability-of-annual-report-on-form-20-f-through-company-website/ [...]

]]>

SAN DIEGO, March 31, 2026 (GLOBE NEWSWIRE) — Belite Bio, Inc (NASDAQ: BLTE), a clinical-stage development company focused on advancing novel therapeutics targeting degenerative retinal diseases that have significant unmet medical needs, today announced that its annual report on Form 20-F, containing audited consolidated financial statements for the year ended December 31, 2025, as filed with the Securities and Exchange Commission on March 31, 2026, is available through its website (https://www.belitebio.com). Shareholders may receive a hard copy of the annual report free of charge upon request. This press release is being issued pursuant to Nasdaq Listing Rule 5250(d)(1)(C).

Click here to view original post

Click Here to Publish/Feature Your Company or Product News with Biotech Networks

]]> https://sdbn.org/san-diego-biotech-news/2026/03/31/emma-health-partners-with-az-gastro-care-to-advance-ibs-treatment-through-microbiome-innovation/ Emma Health Partners with AZ Gastro Care to Advance IBS Treatment Through Microbiome Innovation https://feeds.feedblitz.com/~/952439147/0/sdbnblognews~Emma-Health-Partners-with-AZ-Gastro-Care-to-Advance-IBS-Treatment-Through-Microbiome-Innovation/ Tue, 31 Mar 2026 13:05:55 +0000 https://sdbn.org/san-diego-biotech-news/2026/03/31/emma-health-partners-with-az-gastro-care-to-advance-ibs-treatment-through-microbiome-innovation/ [...]

]]>

Collaboration brings microbiome-based care to patients with Irritable Bowel Syndrome SAN DIEGO, March 31, 2026 /PRNewswire/ — Emma Health, a digital health company transforming chronic condition management by enabling microbiome-based care, today announced a strategic partnership with AZ…

Click here to view original post

Click Here to Publish/Feature Your Company or Product News with Biotech Networks

]]> https://sdbn.org/san-diego-biotech-news/2026/03/30/a-new-way-to-eavesdrop-on-ocean-temperature-in-the-arctic/ A New Way to Eavesdrop on Ocean Temperature in the Arctic https://feeds.feedblitz.com/~/952268213/0/sdbnblognews~A-New-Way-to-Eavesdrop-on-Ocean-Temperature-in-the-Arctic/ Mon, 30 Mar 2026 22:03:11 +0000 https://sdbn.org/san-diego-biotech-news/2026/03/30/a-new-way-to-eavesdrop-on-ocean-temperature-in-the-arctic/ [...]

]]>

New research led by scientists at UC San Diego’s Scripps Institution of Oceanography finds that the travel time of underwater sounds traveling across the Arctic Ocean can be used to precisely measure ocean temperature under the region’s sea ice.

Click here to view original post

Click Here to Publish/Feature Your Company or Product News with Biotech Networks

]]> https://sdbn.org/wp-content/uploads/2026/03/a-new-way-to-eavesdrop-on-ocean-temperature-in-the-arctic-1024x536.png https://sdbn.org/san-diego-biotech-news/2026/03/30/next-generation-innovators-meet-the-2026-chancellors-innovation-awards-finalists/ Next-Generation Innovators: Meet the 2026 Chancellor’s Innovation Awards Finalists https://feeds.feedblitz.com/~/952229327/0/sdbnblognews~NextGeneration-Innovators-Meet-the-Chancellor%e2%80%99s-Innovation-Awards-Finalists/ Mon, 30 Mar 2026 18:06:08 +0000 https://sdbn.org/san-diego-biotech-news/2026/03/30/next-generation-innovators-meet-the-2026-chancellors-innovation-awards-finalists/ [...]

]]>

The finalists for the third annual Chancellor’s Innovation Awards at University of California San Diego represent a new generation of innovators transforming research breakthroughs into lasting advances that address complex societal challenges.

Click here to view original post

Click Here to Publish/Feature Your Company or Product News with Biotech Networks

]]> https://sdbn.org/wp-content/uploads/2026/03/next-generation-innovators-meet-the-2026-chancellors-innovation-awards-finalists-1024x536.png https://sdbn.org/san-diego-biotech-news/2026/03/30/agena-bioscience-announces-launch-of-the-cftr-100-panel-on-the-massarray-system/ Agena Bioscience Announces Launch of the CFTR 100+ Panel on the MassARRAY® System https://feeds.feedblitz.com/~/952199831/0/sdbnblognews~Agena-Bioscience-Announces-Launch-of-the-CFTR-Panel-on-the-MassARRAY%c2%ae-System/ Mon, 30 Mar 2026 15:05:12 +0000 https://sdbn.org/san-diego-biotech-news/2026/03/30/agena-bioscience-announces-launch-of-the-cftr-100-panel-on-the-massarray-system/ [...]

]]> SAN DIEGO–(BUSINESS WIRE)–Agena Bioscience, a global provider of molecular genomics solutions, recently announced the launch of the CFTR 100+ Panel, a multiplex genotyping solution designed to provide expanded coverage of CFTR variants on the MassARRAY® System. The CFTR gene encodes the cystic fibrosis transmembrane conductance regulator, a chloride channel involved in epithelial ion transport. Pathogenic variants in CFTR are associated with cystic fibrosis and related phenotypes. As professi
Click here to view original post

Click Here to Publish/Feature Your Company or Product News with Biotech Networks

]]> https://sdbn.org/san-diego-biotech-news/2026/03/30/anzu-partners-promotes-josh-stiling-to-principal/ Anzu Partners Promotes Josh Stiling to Principal https://feeds.feedblitz.com/~/952198796/0/sdbnblognews~Anzu-Partners-Promotes-Josh-Stiling-to-Principal/ Mon, 30 Mar 2026 14:22:10 +0000 https://sdbn.org/san-diego-biotech-news/2026/03/30/anzu-partners-promotes-josh-stiling-to-principal/ [...]

]]> ATLANTA & BOSTON & SAN DIEGO & TAMPA, Fla. & WASHINGTON–(BUSINESS WIRE)–Anzu Partners has promoted Josh Stiling to Principal on the investment team. His expertise in battery and energy storage tech has been instrumental.
Click here to view original post

Click Here to Publish/Feature Your Company or Product News with Biotech Networks

]]> https://sdbn.org/san-diego-biotech-news/2026/03/27/calidi-biotherapeutics-reports-fourth-quarter-and-full-year-2025-financial-results-and-recent-operational-highlights/ Calidi Biotherapeutics Reports Fourth Quarter and Full-Year 2025 Financial Results and Recent Operational Highlights https://feeds.feedblitz.com/~/951990632/0/sdbnblognews~Calidi-Biotherapeutics-Reports-Fourth-Quarter-and-FullYear-Financial-Results-and-Recent-Operational-Highlights/ Fri, 27 Mar 2026 21:05:57 +0000 https://sdbn.org/san-diego-biotech-news/2026/03/27/calidi-biotherapeutics-reports-fourth-quarter-and-full-year-2025-financial-results-and-recent-operational-highlights/ [...]

]]> SAN DIEGO, March 27, 2026 (GLOBE NEWSWIRE) — Calidi Biotherapeutics Inc. (NYSE American: CLDI) (“Calidi” or the “Company”), a biotechnology company pioneering the development of targeted genetic medicines, today reported its fourth quarter and full-year 2025 operating and financial results and reviewed recent business highlights.

Click here to view original post

Click Here to Publish/Feature Your Company or Product News with Biotech Networks

]]>